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Introduction
Micropapillary variant (MPV) urothelial carcinoma has been 
reported as comprising up to eight percent of contemporary 
urothelial carcinoma cohorts (1-4). The majority of studies 
have reported that MPV urothelial carcinoma portends a 
worse oncologic prognosis and that the tumor demonstrates 
more aggressive histology (3,5-8). The optimal algorithm 
for patients diagnosed with MPV urothelial carcinoma 
remains poorly defined with many researchers arguing that 
even in the setting of non-muscle invasive disease, these 
patients should be taken for early extirpative management. 
As MPV urothelial carcinoma remains an uncommon 
entity, large and multi-institutional studies have not been 
conducted to evaluate the efficacy of neoadjuvant or 
adjuvant chemotherapy. However, retrospective institutional 
studies have suggested that MPV demonstrates a poorer 
response to standard neoadjuvant chemotherapy regimens 
when compared with pure urothelial carcinoma (9,10). The 
mechanism behind this has been poorly understood. The 
recent article by Guo et al. begins to explore the genetic 
differences in MPV compared with urothelial carcinoma (11).
Immunohistochemical evaluation
Previous immunohistochemical evaluations of MPV 
urothelial carcinoma have been performed to determine 
the best markers to identify MPV in bladder cancer 
specimens. Figure 1 demonstrates an H & E stain of MPV 
urothelial carcinoma. GATA 3 (GATA binding protein 3) 
and uroplakin 3 have been reported as reliable markers for 
urothelial tumors although the sensitivity of uroplakin 3 is 
worse than for GATA 3. GATA 3 is a member of a family 
of transcription factors involved in embryogenesis and 
has been reported to be the most sensitive and specific for 
bladder cancer (12,13). Recent studies have reported that 
GATA 3 levels in MPV urothelial carcinoma are similar 
to levels in pure urothelial carcinoma (14). Interestingly, 
while GATA 3 levels are similar between MPV and pure 
urothelial carcinoma, GATA 3 levels have been reported 
to be significantly lower in other variants of urothelial 
carcinoma such as squamous differentiation variant and 
sarcomatoid variant (14,15). The reason for this difference 
is unclear but is likely more reflective of changes in the 
squamous differentiation variant. 
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An additional marker of urothelial carcinoma is p63. 
Wang et al. recently reported that the presence of p63 was 
an independent predictor of worse survival in patients with 
urothelial carcinoma who underwent radical cystectomy 
with urinary diversion (16). Despite the majority of patients 
with pure urothelial carcinoma displaying expression of 
p63, recent studies have reported decreased p63 expression 
in patients with MPV, with between 27% and 54% of MPV 
tumors staining positive for p63 (15,17). 
Choi et al. previously reported that muscle-invasive 
urothelial carcinoma can be divided into luminal, p53-
like luminal, and basal subtypes which were predictive of 
response to chemotherapy and overall tumor behavior (18). 
The pure urothelial carcinoma cases with the basal subtype 
had overexpression of p63 and were more aggressive 
at presentation. These patients were additionally more 
sensitive to traditional neoadjuvant chemotherapy regimens 
(18,19). The luminal subtype demonstrated increased 
PPAR-γ expression and FGFR mutations. The p53-like 
luminal subtype tumors shared PPAR-γ expression and 
FGFR mutations but were notably chemo-resistant to 
current neoadjuvant chemotherapy regimens (18). 
In the recent study by Guo et al., it was reported that 
whereas in the pure urothelial carcinoma cohort 47.2% 
were basal subtype, 24.7% were luminal subtype, and 
28.1% were p53-like luminal subtype, when examining the 
MPV urothelial carcinoma cohort, 2.3% were basal subtype 
(n=1), 51.2% were luminal subtype (n=22), and 46.5% were 
p53-like luminal subtype (n=20) (11). The MPV urothelial 
carcinoma tumors demonstrated, almost uniformly, GATA 
3 and uroplakin 2. Furthermore, the tumors demonstrated 
increased PPAR-γ expression and downregulation of p63. 
When examining the response to chemotherapy among 
MPV tumors, 66% (n=4/6) of tumors in the luminal subtype 
and 45% (n=5/11) of tumors in the p53-like luminal subtype 
group demonstrated response to neoadjuvant chemotherapy, 
similar to prior studies suggesting that the p53-like luminal 
subtype was less likely to respond to chemotherapy. 
Genetic alterations 
Downregulation of miR-296, which is associated with 
upregulation of over 300 downstream genes, was found to 
be a driver in the expression of MPV in the recent study by 
Guo et al. (11). This may be a critical pathway that could 
be targeted to better identify patients with this uncommon 
variant of urothelial carcinoma. Downregulation of miR-
296 has previously been reported to be associated with 
aggressive changes in other cancers including prostate 
cancer (20-23). As part of miR-296 downregulation, 
the RUVBL1 pathway is activated. This is known to be 
associated with genes that play critical roles in metastasis, 
cell growth, and DNA repair. Additionally, RUVBL1 acts 
via p53 to block p53 mediated cellular apoptosis (24). 
Furthermore, as the RUVBL1 pathway has been noted to be 
associated with poor response to traditional chemotherapy, 
it may serve as the mechanism of resistance to cisplatin 
based regimens. Both miR-296 and the RUVBL1 pathway 
could be intervened upon to prevent the aggressive changes 
seen with MPV urothelial carcinoma.
An additional potential intervenable pathway identified 
by the Guo et al. study is PPAR-γ (11). The study found 
that the majority of MPV urothelial carcinoma tumors, 
regardless of p53-like subset, demonstrate upstream 
PPAR-γ expression. PPAR-γ has been postulated as a 
target for muscle invasive bladder cancer and research is 
ongoing into its clinical relevance as a therapeutic target 
(25,26). Troglitazone, a PPAR-γ agonist, induces apoptosis 
and autophagy in bladder cancer cells (27); although more 
research is needed before these agents are used in clinical 
practice. 
Clinical implications
A particularly interesting finding in the Guo et al. study is 
the fact that when examining tumors with MPV sections 
and pure urothelial carcinoma sections, the molecular 
signatures of the urothelial carcinoma sections were similar 
to the MPV sections (11). This finding would imply that 
regardless of the percentage of MPV in a tumor specimen, 
the patient will likely have a more aggressive clinical 
Figure 1 H & E stain of micropapillary variant (MPV) urothelial 
carcinoma. Original magnification ×100.
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progression of disease. Previously, authors have suggested 
that in the setting of only small volume variant histology 
(<5%), a patient could potentially be treated as if their 
tumor were pure urothelial carcinoma; however, the current 
study would suggest that these patients may be more 
similar to the higher volume MPV patients than previously 
understood and may benefit from early radical cystectomy 
with urinary diversion until new chemotherapeutic or 
immunomodulating agents are identified.
The lack of responsiveness to current chemotherapy 
regimens and molecular alterations indicative of an 
aggressive tumor suggest that patients with MPV urothelial 
carcinoma may benefit from early extirpative management. 
The approach to patients with MPV urothelial carcinoma 
will continue to evolve as new molecular targets are 
identified. As previously discussed, miR-296, RUVBL1, and 
PPAR-γ are potential targets that could revolutionize the 
way MPV urothelial carcinoma is approached. 
Conclusions
MPV urothelial carcinoma remains an uncommon variant 
of bladder cancer that can be challenging to treat. Studies 
such as that by Guo et al. are landmark in building an 
understanding of the fundamental changes that occur in 
the development of MPV urothelial carcinoma. With 
subsequent studies of the molecular underpinnings and 
evaluation of therapeutic targets, management of patients 
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